Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORE8394 phase 2 master protocol in BRAF-altered cancers
2024-513578-23-00Phase 2Authorised
- Sponsor
- Fore Biotherapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of plixorafenib and cobicistat in Nonhematologic neoplasms, central nervous system primary tumor, glioma and 1 more (4 arms), sponsored by Fore Biotherapeutics. Primary endpoints: Objective Response Rate and Pharmacokinetics. Planned start Aug 2024; status: authorised.
02
Drugs
plixorafenibcobicistat
03
Conditions
Nonhematologic neoplasmscentral nervous system primary tumorgliomaGlioneuronal Neoplasm
Beyond the preview
Go deeper on 2024-513578-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513578-23-00.